EMA approves Pfizer / BioNTech vaccine for use between 12 and 15 years

last minute “data-mce-href =” https://www.ntv.com.tr/son-minute “> Latest news!

In the statement made by the European Medicines Agency (EMA), it was stated that the effect of the vaccine, which can be given to people 16 years of age and older, is currently being investigated in 2,260 people in the age group 12-15. .

As a result of the research, it was concluded that the vaccine is effective in children in this age group and provides protection against the disease. According to the statement, Kovid-19 disease was not seen in 1005 children who were vaccinated, 16 of the 978 children who received the placebo vaccine were infected.

Marco Caveleri, director of vaccine strategy at the EMA, told the press conference on the subject that the effect of the vaccine in children is the same or even more positive than in young adults.

Stating that the vaccine should be given to children in 2 doses and at least 3 weeks apart, as in adults, Caveleri stressed that side effects in children are the same as in adults.

Caveleri stressed that the EMA has made a recommendation and that the decision whether to give the vaccine to children or when it will be given will be taken by EU member states.

The EU has signed an agreement with companies to purchase an additional 1.8 billion doses of the BioNTech-Pfizer vaccine for 2022-2023. The EU administration said vaccination of the 12-15 age group could start in the fall.

Download the NTV application, be informed of developments

Add a Comment